With the aim of strengthening its pipeline of drugs targeting cancer, inflammation and other conditions, Inspyr Therapeutics has agreed to acquire Lewis and Clark Pharmaceuticals.

Following the all-stock transaction, the target company’s shareholders will own 50% of the acquirer company’s common shares.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The acquirer company is a clinical-stage biotechnology company, whereas the target company is a biotechnology company.

"Nippon Suisan Kaisha’s subsidiary Nissui Pharmaceutical has reached an agreement to its pharmaceutical subsidiary company based in Yamanashi, Japan, to Senshukai."

Both companies involved in the transaction are based in the US.

Nippon Suisan Kaisha’s subsidiary Nissui Pharmaceutical has reached an agreement to its pharmaceutical subsidiary company based in Yamanashi, Japan, to Senshukai.

See Also:

Also based in Japan, the acquirer company is engaged in mail-order business.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.